The Diabetes and Antenatal Milk Expressing ( DAME ) trial will establish whether advising women with diabetes in pregnancy ( pre-existing or gestational ) to express breast milk from 36 weeks gestation increases the proportion of infants who require admission to special or neonatal intensive care units ( SCN/NICU ) compared with infants of women receiving standard care .